Lars Edvinsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3259862/publications.pdf

Version: 2024-02-01

3731 6300 33,624 527 89 158 citations g-index h-index papers 538 538 538 10982 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Biological and small molecule strategies in migraine therapy with relation to the calcitonin geneâ€related peptide family of peptides. British Journal of Pharmacology, 2022, 179, 371-380.	5.4	12
2	Advances in migraine and headache therapy (BJP 75th anniversary). British Journal of Pharmacology, 2022, 179, 355-357.	5.4	0
3	Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors. Journal of Headache and Pain, 2022, 23, 26.	6.0	11
4	Dual action of the cannabinoid receptor 1 ligand arachidonyl-2′-chloroethylamide on calcitonin gene-related peptide release. Journal of Headache and Pain, 2022, 23, 30.	6.0	4
5	Repair-related molecular changes during recovery phase of ischemic stroke in female rats. BMC Neuroscience, 2022, 23, 23.	1.9	4
6	Calcitonin geneâ€related peptide (CGRP) is a key molecule released in acute migraine attacks—Successful translation of basic science to clinical practice. Journal of Internal Medicine, 2022, 292, 575-586.	6.0	15
7	Identifying molecular targets in trigeminal nociception. Nature Reviews Neurology, 2022, 18, 385-386.	10.1	1
8	Secondhand cigarette smoke induces increased expression of contractile endothelin receptors in rat coronary arteries via a MEK1/2 sensitive mechanism. Scandinavian Cardiovascular Journal, 2021, 55, 50-55.	1,2	2
9	Oral rimegepant for migraine prevention. Lancet, The, 2021, 397, 4-5.	13.7	2
10	Identifying New Antimigraine Targets: Lessons from Molecular Biology. Trends in Pharmacological Sciences, 2021, 42, 217-225.	8.7	12
11	CGRP and migraine: from bench to bedside. Revue Neurologique, 2021, 177, 785-790.	1.5	36
12	Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP. Nature Reviews Neurology, 2021, 17, 621-633.	10.1	47
13	The CGRP Family of Neuropeptides and their Receptors in the Trigeminovascular System. Headache, 2021, , 1-12.	0.4	O
14	Ovariectomy reduces vasocontractile responses of rat middle cerebral arteries after focal cerebral ischemia. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	1
15	Neurokinins and their receptors in the rat trigeminal system: Differential localization and release with implications for migraine pain. Molecular Pain, 2021, 17, 174480692110594.	2.1	16
16	Neuropeptides and the Nodes of Ranvier in Cranial Headaches. Frontiers in Physiology, 2021, 12, 820037.	2.8	3
17	Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission. Frontiers in Immunology, 2021, 12, 785072.	4.8	4
18	Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia, 2020, 40, 357-366.	3.9	44

#	Article	IF	CITATIONS
19	Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions. Cephalalgia, 2020, 40, 527-542.	3.9	21
20	Views on migraine pathophysiology: Where does it start?. Neurology and Clinical Neuroscience, 2020, 8, 120-127.	0.4	4
21	Estrogen receptors $\hat{l}\pm$, \hat{l}^2 and GPER in the CNS and trigeminal system - molecular and functional aspects. Journal of Headache and Pain, 2020, 21, 131.	6.0	58
22	Transcriptome profiling revealed early vascular smooth muscle cell gene activation following focal ischemic stroke in female rats – comparisons with males. BMC Genomics, 2020, 21, 883.	2.8	7
23	Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system. Cephalalgia, 2020, 40, 1296-1309.	3.9	21
24	Oxytocin as a regulatory neuropeptide in the trigeminovascular system: Localization, expression and function of oxytocin and oxytocin receptors. Cephalalgia, 2020, 40, 1283-1295.	3.9	19
25	Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies. Journal of Headache and Pain, 2020, 21, 26.	6.0	26
26	The distribution of oxytocin and the oxytocin receptor in rat brain: relation to regions active in migraine. Journal of Headache and Pain, 2020, 21, 10.	6.0	39
27	Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion. Journal of Molecular Neuroscience, 2020, 70, 930-944.	2.3	54
28	CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles. European Journal of Pharmacology, 2020, 875, 173033.	3.5	3
29	Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity. International Journal of Molecular Sciences, 2020, 21, 1343.	4.1	7
30	Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache. Brain Sciences, 2020, 10, 30.	2.3	35
31	Vancouver Declaration II on Global Headache Patient Advocacy 2019. Cephalalgia, 2020, 40, 1017-1025.	3.9	6
32	Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Caseâ€Control and Caseâ€Crossover Settings: A Systematic Review and Metaâ€Analysis. Headache, 2020, 60, 1132-1164.	3.9	28
33	The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmas. European Journal of Pharmacology, 2020, 881, 173205.	3.5	25
34	Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology. Brain, 2020, 143, e13-e13.	7.6	8
35	Trigeminal Mechanisms of Nociception. Headache, 2020, , 3-31.	0.4	O
36	Oxytocin as a regulatory neuropeptide in the trigeminovascular system: localization, expression and function of oxytocin and oxytocin receptors. FASEB Journal, 2020, 34, 1-1.	0.5	0

#	Article	IF	CITATIONS
37	Increased mortality in elderly heart failure patients receiving infusion of furosemide compared to elderly heart failure patients receiving bolus injection. Journal of Geriatric Cardiology, 2020, 17, 359-364.	0.2	1
38	Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine. Journal of Family Practice, 2020, 69, S8-S12.	0.2	6
39	Synergistic effects of a cremophor EL drug delivery system and its U0126 cargo in an <i>ex vivo</i> model. Drug Delivery, 2019, 26, 680-688.	5.7	3
40	Erenumab (AMC 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. Cephalalgia, 2019, 39, 1745-1752.	3.9	30
41	Rimegepant oral disintegrating tablet for migraine. Lancet, The, 2019, 394, 711-712.	13.7	12
42	Does inflammation have a role in migraine?. Nature Reviews Neurology, 2019, 15, 483-490.	10.1	191
43	Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction. European Journal of Pharmacology, 2019, 864, 172726.	3.5	8
44	C-fibers may modulate adjacent Al̃-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. Journal of Headache and Pain, 2019, 20, 105.	6.0	72
45	The Presence of Calcitonin Gene-Related Peptide and Its Receptors in Rat, Pig and Human Brain: Species Differences in Calcitonin Gene-Related Peptide Pharmacology. Pharmacology, 2019, 104, 332-341.	2.2	11
46	Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). Journal of Headache and Pain, 2019, 20, 60.	6.0	24
47	Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models. Cephalalgia, 2019, 39, 1421-1434.	3.9	25
48	The changing faces of migraine. Journal of Headache and Pain, 2019, 20, 52.	6.0	1
49	Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets. CNS Drugs, 2019, 33, 525-537.	5.9	74
50	Discovery of CGRP in relation to migraine. Cephalalgia, 2019, 39, 331-332.	3.9	16
51	Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache. Neurological Sciences, 2019, 40, 75-80.	1.9	9
52	MEK1/2 inhibitor U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after subarachnoid haemorrhage in rats. PLoS ONE, 2019, 14, e0215398.	2.5	14
53	Role of CGRP in Migraine. Handbook of Experimental Pharmacology, 2019, 255, 121-130.	1.8	99
54	Exploration of Physiological and Pathophysiological Implications of miRNA-143 and miRNA-145 in Cerebral Arteries. Journal of Cardiovascular Pharmacology, 2019, 74, 409-419.	1.9	3

#	Article	IF	CITATIONS
55	Mechanisms of migraine as a chronic evolutive condition. Journal of Headache and Pain, 2019, 20, 117.	6.0	137
56	PAC1 receptor mRNA and protein distribution in rat and human trigeminal and sphenopalatine ganglia, spinal trigeminal nucleus and in dura mater. Cephalalgia, 2019, 39, 827-840.	3.9	11
57	MEK/ERK/1/2 sensitive vascular changes coincide with retinal functional deficit, following transient ophthalmic artery occlusion. Experimental Eye Research, 2019, 179, 142-149.	2.6	3
58	CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia, 2019, 39, 354-365.	3.9	64
59	Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia, 2019, 39, 366-373.	3.9	83
60	Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia, 2019, 39, 342-353.	3.9	76
61	Perivascular neurotransmitters: Regulation of cerebral blood flow and role in primary headaches. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 610-632.	4.3	35
62	Pre-clinical effects of highly potent MEK1/2 inhibitors on rat cerebral vasculature after organ culture and subarachnoid haemorrhage. Clinical Science, 2019, 133, 1797-1811.	4.3	8
63	The Therapeutic Impact of New Migraine Discoveries. Current Medicinal Chemistry, 2019, 26, 6261-6281.	2.4	11
64	Smoking and Endothelial Dysfunction. Current Vascular Pharmacology, 2019, 18, 1-11.	1.7	51
65	CGRP as the target of new migraine therapies $\hat{a}\in$ " successful translation from bench to clinic. Nature Reviews Neurology, 2018, 14, 338-350.	10.1	617
66	PACAP and its role in primary headaches. Journal of Headache and Pain, 2018, 19, 21.	6.0	78
67	The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache, 2018, 58, 33-47.	3.9	68
68	Increased endothelinâ€1â€mediated vasoconstriction after organ culture in rat and pig ocular arteries can be suppressed with MEK/ERK1/2 inhibitors. Acta Ophthalmologica, 2018, 96, e619-e625.	1.1	9
69	Acute mitogenâ€activated protein kinase 1/2 inhibition improves functional recovery and vascular changes after ischaemic stroke in ratâ€monitored by 9.4 T magnetic resonance imaging. Acta Physiologica, 2018, 223, e12985.	3.8	11
70	Headache advances in 2017: a new horizon in migraine therapy. Lancet Neurology, The, 2018, 17, 5-6.	10.2	6
71	Contractile Responses in Spontaneously Hypertensive Rats after Transient Middle Cerebral Artery Occlusion. Pharmacology, 2018, 101, 120-132.	2.2	1
72	CGRP Antibodies as Prophylaxis in Migraine. Cell, 2018, 175, 1719.	28.9	37

#	Article	IF	CITATIONS
73	Role of pannexin and adenosine triphosphate (ATP) following myocardial ischemia/reperfusion. Scandinavian Cardiovascular Journal, 2018, 52, 340-343.	1.2	16
74	Expression of Pituitary Adenylate Cyclase-activating Peptide, Calcitonin Gene-related Peptide and Headache Targets in the Trigeminal Ganglia of Rats and Humans. Neuroscience, 2018, 393, 319-332.	2.3	29
75	Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. Journal of Headache and Pain, 2018, 19, 66.	6.0	30
76	PACAP38 and PAC1 receptor blockade: a new target for headache?. Journal of Headache and Pain, 2018, 19, 64.	6.0	59
77	Inhibition of mitogenâ€activated protein kinase 1/2 in the acute phase of stroke improves longâ€term neurological outcome and promotes recovery processes in rats. Acta Physiologica, 2017, 219, 814-824.	3.8	17
78	Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries. Vascular Pharmacology, 2017, 90, 36-43.	2.1	17
79	<pre><scp>T</scp>he <scp>T</scp>rigeminovascular <scp>P</scp>athway: <scp>R</scp>ole of CGRP and CGRP <scp>R</scp>eceptors in <scp>M</scp>igraine. Headache, 2017, 57, 47-55.</pre>	3.9	209
80	Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72). Journal of Headache and Pain, 2017, 18, 39.	6.0	27
81	Blocking CGRP in migraine patients – a review of pros and cons. Journal of Headache and Pain, 2017, 18, 96.	6.0	217
82	Changes in vasodilation following myocardial ischemia/reperfusion in rats. Nitric Oxide - Biology and Chemistry, 2017, 70, 68-75.	2.7	6
83	Endothelin receptor mediated Ca 2+ signaling in coronary arteries after experimentally induced ischemia/reperfusion injury in rat. Journal of Molecular and Cellular Cardiology, 2017, 111, 1-9.	1.9	10
84	Cerebrovascular Gene Expression in Spontaneously Hypertensive Rats After Transient Middle Cerebral Artery Occlusion. Neuroscience, 2017, 367, 219-232.	2.3	6
85	Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca2+ levels in the perfused and non-perfused isolated rat middle cerebral artery. Journal of Headache and Pain, 2017, 18, 61.	6.0	15
86	Enhanced contractility of intraparenchymal arterioles after global cerebral ischaemia in rat $\hat{a} \in \hat{a}$ new insights into the development of delayed cerebral hypoperfusion. Acta Physiologica, 2017, 220, 417-431.	3.8	10
87	Board Walk – October 2017. Cephalalgia, 2017, 37, 1111-1112.	3.9	0
88	Perivascular Neurotransmitter Regulation of Cerebral Blood Flow., 2017,, 70-74.		0
89	Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects. Current Medicinal Chemistry, 2017, 24, 3649-3665.	2.4	42
90	Myocardial ischemia-reperfusion enhances transcriptional expression of endothelin-1 and vasoconstrictor ETB receptors via the protein kinase MEK-ERK1/2 signaling pathway in rat. PLoS ONE, 2017, 12, e0174119.	2.5	26

#	Article	IF	Citations
91	Peripheral Sensory Neurons Expressing Melanopsin Respond to Light. Frontiers in Neural Circuits, 2016, 10, 60.	2.8	50
92	KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL- $1\hat{l}^2$ in the rat trigeminal ganglion. Journal of Headache and Pain, 2016, 17, 64.	6.0	23
93	Reduced Mechanical Stretch Induces Enhanced Endothelin B Receptorâ€Mediated Contractility via Activation of Focal Adhesion Kinase and Extracellular Regulated Kinase 1/2 in Cerebral Arteries from Rat. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 68-77.	2.5	4
94	Contractile Changes in the Vasculature After Subchronic Smoking: A Comparison Between Wild Type and Surfactant Protein D Knock-Out Mice. Nicotine and Tobacco Research, 2016, 18, 642-646.	2.6	5
95	New insights on pyrimidine signalling within the arterial vasculature $\hat{a}\in$ " Different roles for P2Y2 and P2Y6 receptors in large and small coronary arteries of the mouse. Journal of Molecular and Cellular Cardiology, 2016, 93, 1-11.	1.9	25
96	Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience, 2016, 328, 165-183.	2.3	57
97	Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets. Journal of Headache and Pain, 2016, 17, 78.	6.0	33
98	The effects of MEK1/2 inhibition on cigarette smoke exposure-induced ET receptor upregulation in rat cerebral arteries. Toxicology and Applied Pharmacology, 2016, 304, 70-78.	2.8	10
99	Release of PACAP-38 in episodic cluster headache patients – an exploratory study. Journal of Headache and Pain, 2016, 17, 69.	6.0	79
100	Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography. Journal of Comparative Neurology, 2016, 524, 90-118.	1.6	60
101	Mapping the calcitonin receptor in human brain stem. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R788-R793.	1.8	26
102	Similar Adiponectin Levels in Obese Normotensive and Obese Hypertensive Men and No Vasorelaxant Effect of Adiponectin on Human Arteries. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 128-135.	2.5	7
103	Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in Migraine Pathophysiology. Current Topics in Neurotoxicity, 2016, , 609-615.	0.4	2
104	Enhanced Endothelin-1 Mediated Vasoconstriction of the Ophthalmic Artery May Exacerbate Retinal Damage after Transient Global Cerebral Ischemia in Rat. PLoS ONE, 2016, 11, e0157669.	2.5	8
105	A second trigeminal <scp>CGRP</scp> receptor: function and expression of the <scp>AMY</scp> ₁ receptor. Annals of Clinical and Translational Neurology, 2015, 2, 595-608.	3.7	158
106	Dural administration of inflammatory soup or Complete Freund's Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion. Journal of Headache and Pain, 2015, 16, 564.	6.0	45
107	Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion. Journal of Headache and Pain, 2015, 16, 99.	6.0	48
108	Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study. Journal of Headache and Pain, 2015, 16, 555.	6.0	27

7

#	Article	IF	CITATIONS
109	Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. Journal of Headache and Pain, 2015, 16, 91.	6.0	49
110	Endothelin-1 and Endothelin-3 Regulate Endothelin Receptor Expression in Rat Coronary Arteries. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 297-305.	2.5	9
111	The Journey to Establish CGRP as a Migraine Target: A Retrospective View. Headache, 2015, 55, 1249-1255.	3.9	48
112	CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. British Journal of Clinical Pharmacology, 2015, 80, 193-199.	2.4	158
113	Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier. Brain Research, 2015, 1600, 93-109.	2.2	207
114	U0126 Attenuates Cerebral Vasoconstriction and Improves Long-Term Neurologic Outcome after Stroke in Female Rats. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 454-460.	4.3	46
115	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology, The, 2015, 14, 1091-1100.	10.2	221
116	MEK1/2 Inhibitor U0126 but Not Endothelin Receptor Antagonist Clazosentan Reduces Upregulation of Cerebrovascular Contractile Receptors and Delayed Cerebral Ischemia, and Improves Outcome after Subarachnoid Hemorrhage in Rats. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 329-337.	4.3	18
117	<scp>PACAP</scp> and its receptors in migraine pathophysiology: Commentary on Walker <i>et al</i> , Br J Pharmacol 171: 1521–1533. British Journal of Pharmacology, 2015, 172, 4782-4784.	5.4	3
118	The Role of ATP and P2X7 in Upregulation of Vasocontractile ETâ€B Receptors in Basilar Arteries. FASEB Journal, 2015, 29, 949.2.	0.5	0
119	Different Roles for P2Y2 and P2Y6 Receptors in Large and Smaller Coronary Arteries. FASEB Journal, 2015, 29, 644.6.	0.5	0
120	Early MEK1/2 Inhibition after Global Cerebral Ischemia in Rats Reduces Brain Damage and Improves Outcome by Preventing Delayed Vasoconstrictor Receptor Upregulation. PLoS ONE, 2014, 9, e92417.	2.5	20
121	CaMKII inhibition with KN93 attenuates endothelin and serotonin receptor-mediated vasoconstriction and prevents subarachnoid hemorrhage-induced deficits in sensorimotor function. Journal of Neuroinflammation, 2014, 11 , 207 .	7.2	15
122	Differential localization and characterization of functional calcitonin gene-related peptide receptors in human subcutaneous arteries. Acta Physiologica, 2014, 210, 811-822.	3.8	23
123	Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study. Archives of Dermatological Research, 2014, 306, 505-509.	1.9	14
124	Plasticity of Cerebrovascular Smooth Muscle Cells After Subarachnoid Hemorrhage. Translational Stroke Research, 2014, 5, 365-376.	4.2	23
125	Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology, 2014, 83, 958-966.	1.1	235
126	Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. Journal of Headache and Pain, 2014, 15, 22.	6.0	18

#	Article	IF	Citations
127	CaMKII and MEK1/2 inhibition time-dependently modify inflammatory signaling in rat cerebral arteries during organ culture. Journal of Neuroinflammation, 2014, 11, 90.	7.2	15
128	Apolipoprotein B of low-density lipoprotein impairs nitric oxide-mediated endothelium-dependent relaxation in rat mesenteric arteries. European Journal of Pharmacology, 2014, 725, 10-17.	3.5	12
129	Characterization of the contractile P2Y14 receptor in mouse coronary and cerebral arteries. FEBS Letters, 2014, 588, 2936-2943.	2.8	14
130	Pituitary adenylate cyclase activating polypeptide and migraine. Annals of Clinical and Translational Neurology, 2014, 1, 1036-1040.	3.7	124
131	Expression and Characterization of Purinergic Receptors in Rat Middle Meningeal Artery–Potential Role in Migraine. PLoS ONE, 2014, 9, e108782.	2.5	35
132	Brain natriuretic peptide is a potent vasodilator in aged human microcirculation and shows a blunted response in heart failure patients. Journal of Geriatric Cardiology, 2014, 11, 50-6.	0.2	7
133	Early events triggering delayed vasoconstrictor receptor upregulation and cerebral ischemia after subarachnoid hemorrhage. BMC Neuroscience, 2013, 14, 34.	1.9	30
134	MAPK signaling pathway regulates cerebrovascular receptor expression in human cerebral arteries. BMC Neuroscience, 2013, 14, 12.	1.9	23
135	Localization of CGRP Receptor Components, CGRP, and Receptor Binding Sites in Human and Rhesus Cerebellar Cortex. Cerebellum, 2013, 12, 937-949.	2.5	39
136	Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method. Cephalalgia, 2013, 33, 152-159.	3.9	25
137	Secondhand cigarette smoke exposure causes upregulation of cerebrovascular 5â€ <scp>HT</scp> ₁ <scp>₈</scp> receptors <i>via</i> the <scp>R</scp> ERK/ <scp>MAPK</scp> pathway in rats. Acta Physiologica, 2013, 207, 183-193.	3.8	21
138	VIP/PACAP receptors in cerebral arteries of rat: Characterization, localization and relation to intracellular calcium. Neuropeptides, 2013, 47, 85-92.	2.2	37
139	Differentiation of Nerve Fibers Storing CGRP and CGRP Receptors in the Peripheral Trigeminovascular System. Journal of Pain, 2013, 14, 1289-1303.	1.4	201
140	Pearls and pitfalls in neural CGRP immunohistochemistry. Cephalalgia, 2013, 33, 593-603.	3.9	17
141	Role of VIP/PACAP in primary headaches. Cephalalgia, 2013, 33, 1070-1072.	3.9	18
142	Permanent Distal Occlusion of Middle Cerebral Artery in Rat Causes Local Increased ETB, 5-HT1Band AT1Receptor-Mediated Contractility Downstream of Occlusion. Journal of Vascular Research, 2013, 50, 396-409.	1.4	9
143	Is CGRP a marker for chronic migraine?. Neurology, 2013, 81, 1184-1185.	1.1	16
144	Altered Endothelin Receptor Expression and Affinity in Spontaneously Hypertensive Rat Cerebral and Coronary Arteries. PLoS ONE, 2013, 8, e73761.	2.5	16

#	Article	IF	CITATIONS
145	Male-Female Differences in Upregulation of Vasoconstrictor Responses in Human Cerebral Arteries. PLoS ONE, 2013, 8, e62698.	2.5	31
146	CGRP Receptor Antagonism and Migraine Therapy. Current Protein and Peptide Science, 2013, 14, 386-392.	1.4	21
147	Signal transduction in cerebral arteries after subarachnoid hemorrhage ―a phosphoproteomic approach. FASEB Journal, 2013, 27, 700.8.	0.5	0
148	CGRP antagonists for the treatment of migraine: rationale and clinical data. Clinical Investigation, 2012, 2, 73-88.	0.0	3
149	Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience, 2012, 202, 158-168.	2.3	69
150	Basic mechanisms of migraine and its acute treatment., 2012, 136, 319-333.		119
151	Regulation of enhanced cerebrovascular expression of proinflammatory mediators in experimental subarachnoid hemorrhage via the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway. Journal of Neuroinflammation, 2012, 9, 274.	7.2	59
152	In vivo experimental stroke and in vitro organ culture induce similar changes in vasoconstrictor receptors and intracellular calcium handling in rat cerebral arteries. Experimental Brain Research, 2012, 219, 507-520.	1.5	22
153	Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. European Journal of Pharmacology, 2012, 674, 345-351.	3.5	18
154	Calcitonin gene-related peptide and its receptor components in the human sphenopalatine ganglion — Interaction with the sensory system. Brain Research, 2012, 1435, 29-39.	2.2	58
155	Cytokines and growth factors modify the upregulation of contractile endothelin <scp>ET_A</scp> and <scp>ET_B</scp> receptors in rat cerebral arteries after organ culture. Acta Physiologica, 2012, 205, 266-278.	3.8	24
156	Cigarette Smoke Upregulates Rat Coronary Artery Endothelin Receptors In Vivo. PLoS ONE, 2012, 7, e33008.	2.5	31
157	Secondhand Smoke Exposure Causes Bronchial Hyperreactivity via Transcriptionally Upregulated Endothelin and 5-hydroxytryptamine 2A Receptors. PLoS ONE, 2012, 7, e44170.	2.5	18
158	Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Molecular and Cellular Neurosciences, 2011, 46, 333-339.	2.2	73
159	α-Trinositol: A Functional (Non-receptor) Neuropeptide Y Antagonist in Vasculature. Journal of Pharmacy and Pharmacology, 2011, 48, 77-84.	2.4	11
160	Late cerebral ischaemia after subarachnoid haemorrhage: Is cerebrovascular receptor upregulation the mechanism behind?. Acta Physiologica, 2011, 203, 209-224.	3.8	23
161	Blockade of the MEK/ERK Pathway with a Raf Inhibitor Prevents Activation of Pro-Inflammatory Mediators in Cerebral Arteries and Reduction in Cerebral Blood Flow after Subarachnoid Hemorrhage in a Rat Model. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 144-154.	4.3	53
162	Alteration in contractile G-protein coupled receptor expression by moist snus and nicotine in rat cerebral arteries. Toxicology and Applied Pharmacology, 2011, 252, 138-149.	2.8	5

#	Article	IF	Citations
163	Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neuroscience, 2011, 12, 112.	1.9	131
164	Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. European Journal of Pharmacology, 2011, 670, 186-194.	3.5	38
165	Inhibition of cerebrovascular raf activation attenuates cerebral blood flow and prevents upregulation of contractile receptors after subarachnoid hemorrhage. BMC Neuroscience, 2011, 12, 107.	1.9	32
166	Secondhand smoke exposure induces Raf/ERK/MAPK-mediated upregulation of cerebrovascular endothelin ETA receptors. BMC Neuroscience, 2011, 12, 109.	1.9	28
167	Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway. BMC Neuroscience, 2011, 12, 5.	1.9	22
168	The role of tumor necrosis factor- \hat{l}_{\pm} and TNF- \hat{l}_{\pm} receptors in cerebral arteries following cerebral ischemia in rat. Journal of Neuroinflammation, 2011, 8, 107.	7.2	84
169	Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. Journal of Neuroinflammation, 2011, 8, 18.	7.2	1
170	Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene-related peptide via activation of extracellular signal-regulated protein kinase 1/2. Cephalalgia, 2011, 31, 95-105.	3.9	36
171	Tracing neural connections to pain pathways with relevance to primary headaches. Cephalalgia, 2011, 31, 737-747.	3.9	73
172	Improvement in neurological outcome and abolition of cerebrovascular endothelin B and 5-hydroxytryptamine 1B receptor upregulation through mitogen-activated protein kinase kinase 1/2 inhibition after subarachnoid hemorrhage in rats. Journal of Neurosurgery, 2011, 114, 1143-1153.	1.6	34
173	Mechanisms of Migraine and Its Treatment. , 2011, , 239-253.		0
174	Renal and Cardiovascular Role of the Neuropeptide Y Y1 Receptor in Ischaemic Heart Failure Rats. Journal of Pharmacy and Pharmacology, 2010, 51, 1257-1265.	2.4	5
175	Neurogenic inflammation: a study of rat trigeminal ganglion. Journal of Headache and Pain, 2010, 11, 485-495.	6.0	44
176	Upregulation of contractile endothelin type B receptors by lipid-soluble cigarette smoking particles in rat cerebral arteries via activation of MAPK. Toxicology and Applied Pharmacology, 2010, 249, 25-32.	2.8	27
177	NF-kappaB signaling mediates vascular smooth muscle endothelin type B receptor expression in resistance arteries. European Journal of Pharmacology, 2010, 637, 148-154.	3.5	23
178	Comparison of MEK/ERK pathway inhibitors on the upregulation of vascular G-protein coupled receptors in rat cerebral arteries. European Journal of Pharmacology, 2010, 644, 128-137.	3.5	28
179	Subarachnoid hemorrhage induces enhanced expression of thromboxane A2 receptors in rat cerebral arteries. Brain Research, 2010, 1316, 163-172.	2.2	31
180	LPS from Porphyromonas gingivalis increases the sensitivity of contractile response mediated by endothelin-B (ETB) receptors in cultured endothelium-intact rat coronary arteries. Vascular Pharmacology, 2010, 53, 250-257.	2.1	9

#	Article	IF	CITATIONS
181	CGRP Receptor Antagonism and Migraine. Neurotherapeutics, 2010, 7, 164-175.	4.4	78
182	Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia, 2010, 30, 467-474.	3.9	32
183	A relationship between migraine and biliary tract disorders: findings in two Swedish samples of elderly twins. Acta Neurologica Scandinavica, 2010, 122, 286-294.	2.1	9
184	Characterization of the Calcitonin Gene-Related Peptide Receptor Antagonist Telcagepant (MK-0974) in Human Isolated Coronary Arteries. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 746-752.	2.5	66
185	Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approaches. Cephalalgia, 2010, 30, 761-766.	3.9	39
186	Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia, 2010, 30, 1233-1240.	3.9	72
187	Involvement of calcium-calmodulin-dependent protein kinase II in endothelin receptor expression in rat cerebral arteries. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H823-H832.	3.2	13
188	Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Therapeutic Advances in Neurological Disorders, 2010, 3, 369-378.	3.5	83
189	CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews Neurology, 2010, 6, 573-582.	10.1	418
190	Cerebral ischemia induces micro vascular pro-inflammatory cytokine expression via the MEK/ERK pathway. Journal of Neuroinflammation, 2010, 7, 14.	7.2	118
191	Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience, 2010, 169, 683-696.	2.3	275
192	New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet, The, 2010, 376, 645-655.	13.7	99
193	Lipid-soluble cigarette smoking particles induce expression of inflammatory and extracellular-matrix-related genes in rat cerebral arteries. Vascular Health and Risk Management, 2009, 5, 333.	2.3	19
194	Increased perfusion pressure enhances the expression of endothelin (ET $<$ sub $>$ B $<$ /sub $>$) and angiotensin II (AT $<$ sub $>$ 1 $<$ /sub $>$, AT $<$ sub $>$ 2 $<$ /sub $>$) receptors in rat mesenteric artery smooth muscle cells. Blood Pressure, 2009, 18, 78-85.	1.5	9
195	Transcriptional Down-Regulation of Thromboxane A ₂ Receptor Expression via Activation of MAPK ERK1/2, p38/NF-κB Pathways. Journal of Vascular Research, 2009, 46, 162-174.	1.4	12
196	Equal contribution of increased intracranial pressure and subarachnoid blood to cerebral blood flow reduction and receptor upregulation after subarachnoid hemorrhage. Journal of Neurosurgery, 2009, 111, 978-987.	1.6	23
197	Telcagepant provides new hope for people with migraine. Nature Reviews Neurology, 2009, 5, 240-242.	10.1	4
198	Enhanced cerebrovascular expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 via the MEK/ERK pathway during cerebral ischemia in the rat. BMC Neuroscience, 2009, 10, 56.	1.9	55

#	Article	IF	CITATIONS
199	Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease. BMC Cardiovascular Disorders, 2009, 9, 40.	1.7	32
200	Brainstem and Thalamic Projections from a Craniovascular Sensory Nervous Centre in the Rostral Cervical Spinal Dorsal Horn of Rats. Cephalalgia, 2009, 29, 935-948.	3.9	60
201	Cerebrovascular Endothelin Receptor Upregulation in Cerebral Ischemia. Current Vascular Pharmacology, 2009, 7, 26-33.	1.7	23
202	Influence of Ageing on Vasomotor Responses of Human Epicardial Coronary Arteries. Basic and Clinical Pharmacology and Toxicology, 2008, 86, 183-191.	0.0	0
203	Modulation of Contractile Force by Endothelin Receptors in Porcine Myocardial Trabeculae. Basic and Clinical Pharmacology and Toxicology, 2008, 87, 185-192.	0.0	0
204	Aspects on the Pathophysiology of Migraine and Cluster Headache. Basic and Clinical Pharmacology and Toxicology, 2008, 89, 65-73.	0.0	3
205	CGRP blockers in migraine therapy: where do they act?. British Journal of Pharmacology, 2008, 155, 967-969.	5.4	57
206	Comparison of CGRP and NO Responses in the Human Peripheral Microcirculation of Migraine and Control Subjects. Cephalalgia, 2008, 28, 563-566.	3.9	26
207	The Blood-Brain Barrier in Migraine Treatment. Cephalalgia, 2008, 28, 1245-1258.	3.9	75
208	Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neuroscience, 2008, 9, 85.	1.9	62
209	Up-regulation of endothelin type B receptors in the human internal mammary artery in culture is dependent on protein kinase C and mitogen-activated kinase signaling pathways. BMC Cardiovascular Disorders, 2008, 8, 21.	1.7	9
210	Central projections of the sensory innervation of the rat middle meningeal artery. Brain Research, 2008, 1208, 103-110.	2.2	62
211	Endothelin receptor-mediated vasodilatation: Effects of organ culture. European Journal of Pharmacology, 2008, 579, 233-240.	3.5	16
212	PKC and MAPK signalling pathways regulate vascular endothelin receptor expression. European Journal of Pharmacology, 2008, 580, 190-200.	3.5	26
213	Enhanced expression of contractile endothelin ETB receptors in rat coronary artery after organ culture. European Journal of Pharmacology, 2008, 582, 94-101.	3.5	18
214	Cerebrovascular Angiotensin AT1 Receptor Regulation in Cerebral Ischemia. Trends in Cardiovascular Medicine, 2008, 18, 98-103.	4.9	13
215	Up-regulation of thromboxane A2 receptor expression by lipid soluble smoking particles through post-transcriptional mechanisms. Atherosclerosis, 2008, 196, 608-616.	0.8	25
216	CGRP-receptor antagonism in migraine treatment. Lancet, The, 2008, 372, 2089-2090.	13.7	37

#	Article	IF	CITATIONS
217	Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. Journal of Headache and Pain, 2008, 9, 5-12.	6.0	60
218	Lipid-Soluble Smoke Particles Upregulate Vascular Smooth Muscle ETB Receptors via Activation of Mitogen-Activating Protein Kinases and NF-kappaB Pathways. Toxicological Sciences, 2008, 106, 546-555.	3.1	52
219	Subtype Activation and Interaction of Protein Kinase C and Mitogen-Activated Protein Kinase Controlling Receptor Expression in Cerebral Arteries and Microvessels After Subarachnoid Hemorrhage. Stroke, 2008, 39, 185-190.	2.0	59
220	Cerebrovascular ET _B , 5-HT _{1B} , and AT ₁ receptor upregulation correlates with reduction in regional CBF after subarachnoid hemorrhage. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3750-H3758.	3.2	59
221	Transcriptional regulation of inflammatory and extracellular matrix–regulating genes in cerebral arteries following experimental subarachnoid hemorrhage in rats. Journal of Neurosurgery, 2007, 107, 1015-1022.	1.6	39
222	Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opinion on Therapeutic Targets, 2007, 11, 1179-1188.	3.4	24
223	CGRP-Receptor Antagonism in Migraine Treatment. CNS and Neurological Disorders - Drug Targets, 2007, 6, 240-246.	1.4	24
224	Inhibitory effect of BIBN4096BS, CGRP8-37 , a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. British Journal of Pharmacology, 2007, 150, 633-640.	5.4	99
225	Pharmacokinetic and Pharmacodynamic Variability as Possible Causes for Different Drug Responses in Migraine. A Comment. Cephalalgia, 2007, 27, 1091-1093.	3.9	13
226	Protein kinase C inhibition attenuates vascular ETBreceptor upregulation and decreases brain damage after cerebral ischemia in rat. BMC Neuroscience, 2007, 8, 7.	1.9	23
227	Enhanced expression of CGRP in rat trigeminal ganglion neurons during cell and organ culture. Brain Research, 2007, 1173, 6-13.	2.2	22
228	Effect of two novel CGRP-binding compounds in a closed cranial window rat model. European Journal of Pharmacology, 2007, 567, 117-124.	3.5	39
229	Cooperative effect of angiotensin AT1 and endothelin ETA receptor antagonism limits the brain damage after ischemic stroke in rat. European Journal of Pharmacology, 2007, 570, 142-148.	3.5	26
230	MEK1/2 inhibition attenuates vascular ETA and ETB receptor alterations after cerebral ischaemia. Experimental Brain Research, 2007, 178, 470-476.	1.5	50
231	Cerebral ischemia induces transcription of inflammatory and extracellular-matrix-related genes in rat cerebral arteries. Experimental Brain Research, 2007, 183, 499-510.	1.5	50
232	Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat. Journal of Headache and Pain, 2007, 8, 83-89.	6.0	7
233	Reduced responsiveness of cutaneous microcirculation in essential hypertension – A pilot study. Blood Pressure, 2006, 15, 275-280.	1.5	35
234	Involvement of Protein Kinases on the Upregulation of Endothelin Receptors in Rat Basilar and Mesenteric Arteries. Experimental Biology and Medicine, 2006, 231, 403-411.	2.4	12

#	Article	IF	Citations
235	Smoking particles enhance endothelin A and endothelin B receptor-mediated contractions by enhancing translation in rat bronchi. BMC Pulmonary Medicine, 2006, 6, 6.	2.0	24
236	Gene expression profiling in the human middle cerebral artery after cerebral ischemia. European Journal of Neurology, 2006, 13, 1324-1332.	3.3	66
237	<scp>Future Preventive Therapy: Are There Promising Drug Targets?</scp> . Headache Currents: A Journal for Recent Advances in Headache and Facial Pain, 2006, 3, 101-107.	0.7	0
238	Neuronal Signal Substances as Biomarkers of Migraine. Headache, 2006, 46, 1088-1094.	3.9	24
239	Clinical Data on the CGRP Antagonist BIBN4096BS for Treatment of Migraine Attacks. CNS Neuroscience & Therapeutics, 2006, 11 , 69-76.	4.0	27
240	Up-Regulation of alpha1A-Adrenoceptors in Rat Mesenteric Artery Involves Intracellular Signal Pathways. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 61-67.	2.5	13
241	Angiotensin II-induced vasodilatation in cerebral arteries is mediated by endothelium-derived hyperpolarising factor. European Journal of Pharmacology, 2006, 531, 259-263.	3.5	18
242	Vascular endothelin ETB receptor-mediated contraction requires phosphorylation of ERK1/2 proteins. European Journal of Pharmacology, 2006, 538, 124-131.	3.5	21
243	Lipid-soluble smoke particles damage endothelial cells and reduce endothelium-dependent dilatation in rat and man. BMC Cardiovascular Disorders, 2006, 6, 3.	1.7	42
244	Gene expression and molecular changes in cerebral arteries following subarachnoid hemorrhage in the rat. Journal of Neurosurgery, 2006, 105, 438-444.	1.6	81
245	Future Preventive Therapy: Are There Promising Drug Targets?. Headache Currents: A Journal for Recent Advances in Headache and Facial Pain, 2006, 3, 101-107.	0.7	0
246	Neuropeptide Y and the cerebral circulation. , 2006, , 105-112.		5
247	Endothelin in the Airways. , 2006, , 1289-1292.		0
248	Triptans Induce Vasoconstriction of Human Arteries and Veins from the Thoracic Wall. Journal of Cardiovascular Pharmacology, 2005, 45, 476-484.	1.9	38
249	Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clinical Science, 2005, 109, 335-342.	4.3	58
250	Presence and Function of the Calcitonin Gene-Related Peptide Receptor on Rat Pial Arteries Investigated In Vitro and In Vivo. Cephalalgia, 2005, 25, 424-432.	3.9	38
251	Correlation between CGRP and Migraine Attacks. Cephalalgia, 2005, 25, 163-164.	3.9	6
252	Reduction of Homocysteine in Elderly with Heart Failure Improved Vascular Function and Blood Pressure Control but did Not Affect Inflammatory Activity. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 306-310.	2.5	23

#	Article	IF	Citations
253	Expression of Inducible Nitric Oxide Synthase in Trigeminal Ganglion Cells during Culture. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 355-363.	2.5	12
254	Vasodilator Effect of Endothelin in Cutaneous Microcirculation of Heart Failure Patients. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 80-85.	2.5	10
255	Neurobiology in primary headaches. Brain Research Reviews, 2005, 48, 438-456.	9.0	209
256	Mitogen activated protein kinase inhibition attenuate cerebral blood flow reduction and abolish cerebral artery receptor upregulation after subarachnoid haemorrhage in rat. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S2-S2.	4.3	0
257	Temporary cerebral ischaemia upregulates the 5-HT1 receptor in the middle cereral artery. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S36-S36.	4.3	0
258	TNF-alpha and EGF potentiate the ETB receptor mediated contraction in rat middle cerebral arteries. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S14-S14.	4.3	0
259	Gene expression in human cerebral arteries. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S520-S520.	4.3	0
260	The importance of extracellular calcium for endothelin type A and B receptor-mediated contraction in rat basilar artery. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S12-S12.	4.3	0
261	Upregulation of contractile ETB receptors in middle cerebral arteries is dependent on PKC. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S40-S40.	4.3	0
262	Cerebral Ischemia Enhances Vascular Angiotensin AT ₁ Receptor–Mediated Contraction in Rats. Stroke, 2004, 35, 970-974.	2.0	103
263	Analysis of ET-A and ET-B receptors using an isolated perfused rat lung preparation. Acta Physiologica Scandinavica, 2004, 181, 259-264.	2.2	4
264	Blockade of CGRP Receptors in the Intracranial Vasculature: A New Target in the Treatment of Headache. Cephalalgia, 2004, 24, 611-622.	3.9	110
265	Up-Regulation of Endothelin Receptor Function and mRNA Expression in Airway Smooth Muscle Cells Following Sephadex-Induced Airway Inflammation. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 43-48.	2.5	11
266	Transcriptional Upâ€Regulation in Expression of 5â€Hydroxytryptamine _{2A} and Transcriptional Downâ€Regulation of Angiotensin II type 1 Receptors during Organ Culture of Rat Mesenteric Artery. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 280-287.	2.5	17
267	Importance of ERK1/2 in upregulation of endothelin type B receptors in cerebral arteries. British Journal of Pharmacology, 2004, 142, 1155-1161.	5.4	65
268	Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. British Journal of Pharmacology, 2004, 143, 697-704.	5.4	112
269	Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries. British Journal of Pharmacology, 2004, 143, 1066-1073.	5.4	17
270	Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides, 2004, 25, 2105-2114.	2.4	30

#	Article	IF	CITATIONS
271	Central projections of sensory innervation of the rat superior sagittal sinus. Neuroscience, 2004, 129, 431-437.	2.3	71
272	Immunoreactivity of NOS, CGRP, PACAP, SP and VIP in the trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2 of the cat. Journal of Headache and Pain, 2003, 4, 156-163.	6.0	16
273	In-depth characterization of CGRP receptors in human intracranial arteries. European Journal of Pharmacology, 2003, 481, 207-216.	3.5	58
274	Role of mitogen-activated protein kinases in endothelin ETB receptor up-regulation after organ culture of rat mesenteric artery. European Journal of Pharmacology, 2003, 482, 39-47.	3.5	33
275	Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Research, 2003, 964, 179-186.	2.2	57
276	Central projections of sensory innervation of the rat superficial temporal artery. Brain Research, 2003, 966, 126-133.	2.2	35
277	Endothelium-Dependent Relaxant Responses to Selective 5-HT _{1B/1D} Receptor Agonists in the Isolated Middle Cerebral Artery of the Rat. Journal of Vascular Research, 2003, 40, 561-566.	1.4	25
278	Investigation of CGRP Receptors and Peptide Pharmacology in Human Coronary Arteries. Characterization with a Nonpeptide Antagonist. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 326-333.	2.5	49
279	Intracellular Pathways Involved in Upregulation of Vascular Endothelin Type B Receptors in Cerebral Arteries of the Rat. Stroke, 2003, 34, 1479-1483.	2.0	61
280	Subarachnoid hemorrhageâ€"induced upregulation of the 5-HT1B receptor in cerebral arteries in rats. Journal of Neurosurgery, 2003, 99, 115-120.	1.6	69
281	New therapeutic target in primary headaches $\hat{a}\in$ blocking the CGRP receptor. Expert Opinion on Therapeutic Targets, 2003, 7, 377-383.	3.4	52
282	Subarachnoid Hemorrhage Enhances Endothelin Receptor Expression and Function in Rat Cerebral Arteries. Neurosurgery, 2003, 52, 1188-1195.	1.1	91
283	Cutaneous vascular reactivity is reduced in aging and in heart failure: association with inflammation. Clinical Science, 2003, 105, 699-707.	4.3	47
284	Subarachnoid Hemorrhage Enhances Endothelin Receptor Expression and Function in Rat Cerebral Arteries. Neurosurgery, 2003, 52, 1188-1195.	1.1	81
285	New therapeutic target in primary headaches? blocking the CGRP receptor. Expert Opinion on Therapeutic Targets, 2003, 7, 377-383.	3.4	2
286	Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries. Neurosurgery, 2003, 52, 1188-94; 1194-5.	1.1	54
287	Enhanced vasodilator responses to calcitonin gene-related peptide (CGRP) in subcutaneous arteries in human hypertension. Journal of Human Hypertension, 2002, 16, 53-59.	2.2	12
288	Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain, 2002, 125, 1392-1401.	7.6	92

#	Article	IF	Citations
289	Expression of ET A and ET B receptor mRNA in human cerebral arteries. British Journal of Neurosurgery, 2002, 16, 149-153.	0.8	25
290	Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. NeuroReport, 2002, 13, 507-509.	1.2	79
291	Human Endothelin Subtype A Receptor Enhancement during Tissue Culture via de Novo Transcription. Neurosurgery, 2002, 50, 127-136.	1.1	22
292	Cerebral Ischemia Upregulates Vascular Endothelin ET _B Receptors in Rat. Stroke, 2002, 33, 2311-2316.	2.0	127
293	Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neuroscience Letters, 2002, 330, 223-226.	2.1	80
294	Calcitonin Gene-Related Peptide (CGRP) in Cerebrovascular Disease. Scientific World Journal, The, 2002, 2, 1484-1490.	2.1	22
295	Organ culture: a new model for vascular endothelium dysfunction. BMC Cardiovascular Disorders, 2002, 2, 8.	1.7	28
296	Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. European Journal of Pharmacology, 2002, 434, 49-53.	3.5	104
297	Protein kinase C inhibitors decrease endothelin ETB receptor mRNA expression and contraction during organ culture of rat mesenteric artery. European Journal of Pharmacology, 2002, 452, 215-222.	3.5	26
298	Analysis of the time course for organ culture-induced endothelin ETB receptor upregulation in rat mesenteric arteries. European Journal of Pharmacology, 2002, 454, 209-215.	3.5	25
299	Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochemical Pharmacology, 2002, 64, 497-505.	4.4	31
300	Neuropeptide Expression in the Human Trigeminal Nucleus Caudalis and in the Cervical Spinal Cord C1 and C2. Cephalalgia, 2002, 22, 112-116.	3.9	99
301	An Immunocytochemical Investigation of Human Trigeminal Nucleus Caudalis: Cgrp, Substance P and 5-Ht1D-Receptor Immunoreactivities Are Expressed by Trigeminal Sensory Fibres. Cephalalgia, 2002, 22, 424-431.	3.9	60
302	Immunohistochemical Localization of Calcitonin Receptor–Like Receptor and Receptor Activity–Modifying Proteins in the Human Cerebral Vasculature. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 620-629.	4.3	120
303	Neuronal messengers in the human cerebral circulation. Peptides, 2001, 22, 995-1007.	2.4	116
304	In depth pharmacological characterization of endothelin B receptors in the rat middle cerebral artery. Neuroscience Letters, 2001, 314, 69-72.	2.1	40
305	4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity?. Neuropharmacology, 2001, 40, 520-525.	4.1	33
306	Calcitonin Gene???Related Peptide (CGRP) and the Pathophysiology of Headache. CNS Drugs, 2001, 15, 745-753.	5.9	64

#	Article	IF	Citations
307	Enhanced Ca2+-induced contractions and attenuated α-adrenoceptor responses in resistance arteries from rats with congestive heart failure. European Journal of Heart Failure, 2001, 3, 7-13.	7.1	4
308	Amylin: Localization, Effects on Cerebral Arteries and on Local Cerebral Blood Flow in the Cat. Scientific World Journal, The, 2001, 1, 168-180.	2.1	50
309	Immunohistochemical Localization of Calcitonin Receptor-Like Receptor and Receptor Activity Modifying Proteins in Human Cerebral and Cranial Vasculature. Scientific World Journal, The, 2001, 1, 48-48.	2.1	0
310	CGRP in Primary Headaches. Scientific World Journal, The, 2001, 1, 29-29.	2.1	0
311	Selective up-regulation of 5-HT1B/1D receptors during organ culture of cerebral arteries. NeuroReport, 2001, 12, 1605-1608.	1.2	39
312	Vasoactive intestinal peptide has a direct positive inotropic effect on isolated human myocardial trabeculae. Clinical Science, 2001, 101, 637-643.	4.3	10
313	Sensory Nerves in Man and Their Role in Primary Headaches. Cephalalgia, 2001, 21, 761-764.	3.9	24
314	Enhanced endothelinâ€1â€induced contractions in mesenteric arteries from rats with congestive heart failure: role of ET _B receptors. European Journal of Heart Failure, 2001, 3, 293-299.	7.1	8
315	Pathophysiology of primary headaches. Current Pain and Headache Reports, 2001, 5, 71-78.	2.9	14
316	Neuropeptide Localization in the â€~Migraine Generator' Region of the Human Brainstem. Cephalalgia, 2001, 21, 96-101.	3.9	99
317	Origin and co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microscopy Research and Technique, 2001, 53, 221-228.	2.2	100
318	Endocardial expression and functional characterization of endothelin-1. Molecular and Cellular Biochemistry, 2001, 224, 151-158.	3.1	8
319	Neuropeptide Yâ€"Mediated Constriction and Dilation in Rat Middle Cerebral Arteries. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 77-84.	4.3	49
320	Evidence that ET-1, but not ET-3 and S6b, ETA -receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-activation of ETB receptors. British Journal of Pharmacology, 2001, 133, 927-935.	5.4	36
321	CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with $\hat{a} \in \mathbb{C}$ Compound $\hat{a} \in \mathbb{C}$ (WO98/11128), a non-peptide antagonist. British Journal of Pharmacology, 2001, 133, 1405-1413.	5.4	33
322	5-HT1B and 5-HT1D receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Research, 2001, 909, 112-120.	2.2	137
323	Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. European Journal of Pharmacology, 2001, 415, 39-44.	3.5	65
324	Characterization of CGRP1 receptors in the guinea pig basilar artery. European Journal of Pharmacology, 2001, 414, 249-258.	3.5	25

#	Article	IF	Citations
325	Sensory nerves in man and their role in primary headaches. Cephalalgia, 2001, 21, 761-764.	3.9	32
326	Characterisation of angiotensin II receptors in isolated human subcutaneous resistance arteries. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S37-S41.	1.7	3
327	Evidence for a cyclic AMP-dependent pathway in angiotensin AT1-receptor activation of human omental arteries. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S42-S47.	1.7	3
328	Aspects on the Pathophysiology of Migraine and Cluster Headache. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 65-73.	0.0	55
329	Increased sensitivity to ET-1 in rat cerebral arteries following organ culture. NeuroReport, 2000, 11, 649-652.	1.2	29
330	The stable pyrimidines UDPÎ ² S and UTPÎ ³ S discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. British Journal of Pharmacology, 2000, 131, 51-56.	5.4	69
331	Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae. European Journal of Pharmacology, 2000, 397, 373-382.	3.5	50
332	CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes. European Journal of Pharmacology, 2000, 408, 183-193.	3.5	32
333	A pathophysiological view of primary headaches. Functional Neurology, 2000, 15 Suppl 3, 50-60.	1.3	0
334	Functional Effects of Neuropeptide Y Receptors on Blood Flow and Nitric Oxide Levels in the Human Nose. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1724-1728.	5.6	29
335	Dilatory responses to acetylcholine, calcitonin gene-related peptide and substance P in the congestive heart failure rat. Acta Physiologica Scandinavica, 1999, 165, 15-23.	2.2	14
336	Decreased responsiveness of vascular postjunctional $\hat{l}\pm 1$ -, $\hat{l}\pm 2$ -adrenoceptors and neuropeptide Y1 receptors in rats with heart failure. Acta Physiologica Scandinavica, 1999, 166, 285-291.	2.2	18
337	Possible Antimigraine Mechanisms of Action of the 5HT1F Receptor Agonist LY334370. Cephalalgia, 1999, 19, 851-858.	3.9	108
338	Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. British Journal of Pharmacology, 1999, 128, 1133-1140.	5.4	115
339	Helospectin-Like Peptides: Immunochemical Localization and Effects on Isolated Cerebral Arteries and on Local Cerebral Blood Flow in the Cat. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 61-67.	4.3	12
340	Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. Neuropeptides, 1999, 33, 41-46.	2.2	54
341	Expression of calcitonin gene-related peptide-1 receptor mRNA in human tooth pulp and trigeminal ganglion. Archives of Oral Biology, 1999, 44, 1-6.	1.8	22
342	Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Research, 1999, 826, 193-199.	2.2	100

#	Article	IF	CITATIONS
343	Altered ratio of endothelin ETA- and ETB receptor mRNA in bronchial biopsies from patients with asthma and chronic airway obstruction. European Journal of Pharmacology, 1999, 365, R1-R3.	3.5	17
344	Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. European Journal of Pharmacology, 1999, 372, 49-56.	3.5	187
345	Cytokines induce increased endothelin ETB receptor-mediated contraction. European Journal of Pharmacology, 1999, 376, 223-232.	3.5	31
346	The human superior cervical ganglion: neuropeptides and peptide receptors. Neuroscience Letters, 1999, 263, 121-124.	2.1	32
347	Messenger molecules and receptor mRNA in the human trigeminal ganglion. Journal of the Autonomic Nervous System, 1999, 76, 176-183.	1.9	176
348	Interleukin- $1\hat{l}^2$ potentiates endothelin ETB receptor-mediated contraction in cultured segments of human temporal artery. Regulatory Peptides, 1999, 81, 89-95.	1.9	18
349	Cytokines increase endothelin ETB receptor contractile activity in rat cerebral artery. NeuroReport, 1999, 10, 2355-2359.	1.2	37
350	INCREASED LEVELS OF ENDOTHELIN ETBRECEPTOR mRNA IN HUMAN OMENTAL ARTERIES AFTER ORGAN CULTURE: QUANTIFICATION BY COMPETITIVE REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 788-794.	1.9	18
351	P2U-receptor mediated endothelium-dependent but nitric oxide-independent vascular relaxation. British Journal of Pharmacology, 1998, 123, 719-729.	5.4	45
352	Neuropeptides in headache. European Journal of Neurology, 1998, 5, 329-341.	3.3	84
353	Appearance of contractile endothelinâ€B receptors in rat mesenteric arterial segments following organ culture. Acta Physiologica Scandinavica, 1998, 163, 121-129.	2.2	46
354	Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: Cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. Journal of the Autonomic Nervous System, 1998, 70, 15-22.	1.9	104
355	Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides, 1998, 19, 1213-1225.	2.4	70
356	Regional variation in appearance of vascular contractile endothelin-B receptors following organ culture. Cardiovascular Research, 1998, 37, 254-262.	3.8	52
357	Transcriptional regulated plasticity of vascular contractile endothelin ETB receptors after organ culture. European Journal of Pharmacology, 1997, 329, 69-77.	3.5	45
358	Expression of calcitonin gene-related peptide1 receptor mRNA in human trigeminal ganglia and cerebral arteries. Neuroscience Letters, 1997, 229, 209-211.	2.1	57
359	Innervation Pattern of Malformative Cortical Vessels in Sturge-Weber Disease: An Histochemical, Immunohistochemical, and Ultrastructural Study. Neurosurgery, 1997, 41, 872-877.	1.1	34
360	Differential Effects of Increasing Doses of αâ€Trinositol on Cerebral Blood Flow Autoregulation. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 38-43.	0.0	3

#	Article	IF	Citations
361	Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H $_1$ - and H $_2$ -receptors by RT-PCR. British Journal of Pharmacology, 1997, 121, 41-48.	5.4	41
362	Release of Histamine from Dural Mast Cells by Substance P and Calcitonin Gene-Related Peptide. Cephalalgia, 1997, 17, 166-174.	3.9	176
363	Presence of Contractile Endothelin-A and Dilatory Endothelin-B Receptors in Human Cerebral Arteries. Neurosurgery, 1997, 40, 346-353.	1.1	71
364	Effects of phosphorothioated neuropeptide YY1-receptor antisense oligodeoxynucleotide in conscious rats and in human vessels. British Journal of Pharmacology, 1996, 118, 131-136.	5.4	9
365	Tyrphostin inhibition of ATPâ€stimulated DNA synthesis, cell proliferation and Fosâ€protein expression in vascular smooth muscle cells. British Journal of Pharmacology, 1996, 118, 1028-1034.	5.4	21
366	Plasticity of contractile endothelinâ€B receptors in human arteries after organ culture. British Journal of Pharmacology, 1996, 119, 1159-1166.	5.4	92
367	Presence of neuropeptide Y Y1 receptor mediating vasoconstriction in human cerebral arteries. Neuroscience Letters, 1996, 204, 145-148.	2.1	29
368	Nitroxidergic innervation of guinea pig cerebral arteries. Journal of the Autonomic Nervous System, 1996, 58, 108-114.	1.9	33
369	Characterization of Neuropeptide Y Receptors Mediating Contraction, Potentiation and Inhibition of Relaxation. Blood Pressure, 1996, 5, 164-169.	1.5	21
370	Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. Brain Research, 1996, 707, 110-118.	2.2	83
371	Calcitonin Gene-Related Peptide is Released from Capsaicin-Sensitive Nerve Fibres and Induces Vasodilatation of Human Cerebral Arteries Concomitant with Activation of Adenylyl Cyclase. Cephalalgia, 1996, 16, 310-316.	3.9	133
372	Neuropeptide Changes in a case of Chronic Paroxysmal Hemicrania—Evidence for Trigemino-Parasympathetic Activation. Cephalalgia, 1996, 16, 448-450.	3.9	141
373	Characterization of Endothelin Receptors in the Cerebral Vasculature and Their Lack of Effect on Spreading Depression. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 698-704.	4.3	21
374	Vascular alpha-2 adrenoceptor function is decreased in rats with congestive heart failure. Cardiovascular Research, 1996, 31, 577-584.	3.8	13
375	Contractile Effects of Neuropeptide Y in Human Subcutaneous Resistance Arteries Are Mediated by Y1 Receptors. Journal of Cardiovascular Pharmacology, 1996, 28, 764-768.	1.9	25
376	Relation between Cyclic GMP Generation and Cerebrovascular Reactivity: Modulation by NPY and αâ€Trinositol. Basic and Clinical Pharmacology and Toxicology, 1995, 77, 48-56.	0.0	17
377	Modulation of vascular contractile responses to α ₁ â€and α ₂ â€adrenergic and neuropeptide Y receptor stimulation in rats with ischaemic heart failure. Acta Physiologica Scandinavica, 1995, 154, 429-437.	2.2	13
378	Alterations in perivascular dilatory neuropeptides (CGRP, SP, VIP) in the external jugular vein and in the cerebrospinal fluid following subarachnoid haemorrhage in man. Acta Neurochirurgica, 1995, 132, 32-41.	1.7	74

#	Article	IF	CITATIONS
379	Neuropeptides in the Cerebral Circulation: Relevance to Headache. Cephalalgia, 1995, 15, 272-276.	3.9	97
380	Modification of Vasoconstrictor Responses in Cerebral Blood Vessels by Lesioning of The Trigeminal Nerve: Possible Involvement of CGRP. Cephalalgia, 1995, 15, 373-383.	3.9	27
381	Modification of vasoconstrictor responses in cerebral blood vessels by lesioning of the trigeminal nerve: Possible involvement of CGRP. Cephalalgia, 1995, 15, 373-383.	3.9	49
382	Peptidergic innervation of guinea-pig brain vessels: comparison with immunohistochemistry and in vitro pharmacology in rostrally and caudally located arteries. Journal of the Autonomic Nervous System, 1995, 55, 179-188.	1.9	12
383	The peptidergic innervation of the human superficial temporal artery: Immunohistochemistry, ultrastructure, and vasomotility. Peptides, 1995, 16, 275-287.	2.4	34
384	Demonstration of Neuropeptide Containing Nerves and Vasomotor Responses to Perivascular Peptides in Human Cerebral Arteries. Cephalalgia, 1994, 14, 88-96.	3.9	57
385	Endothelins: A Role in Cerebrovascular Disease?. Cephalalgia, 1994, 14, 259-265.	3.9	25
386	Neuropeptides in Migraine and Cluster Headache. Cephalalgia, 1994, 14, 320-327.	3.9	169
387	Histamineâ€Independent Modulation of the Neuropeptide Yâ€Induced Pressor Response by αâ€Trinositol in the Pithed Rat. Basic and Clinical Pharmacology and Toxicology, 1994, 75, 371-376.	0.0	3
388	Hypercapnic vasodilatation in isolated rat basilar arteries is exerted via low pH and does not involve nitric oxide synthase stimulation or cyclic GMP production. Acta Physiologica Scandinavica, 1994, 152, 391-397.	2.2	42
389	Relationships between plasma levels of catecholamines and neuropeptides and the survival time in patients with congestive heart failure. Journal of Internal Medicine, 1994, 235, 595-601.	6.0	13
390	Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)-I D Receptor Agonist 311C90. Headache, 1994, 34, 394-399.	3.9	170
391	Innervation of the human cerebral circulation. Journal of the Autonomic Nervous System, 1994, 49, 91-96.	1.9	13
392	Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. Journal of the Autonomic Nervous System, 1994, 49, 97-103.	1.9	38
393	Characterization of the histamine receptors in the guineaâ€pig lung: evidence for relaxant histamine H ₃ receptors in the trachea. British Journal of Pharmacology, 1994, 111, 445-454.	5.4	31
394	Calcitonin gene-related peptide (human α-CGRP) counteracts vasoconstriction in human subarachnoid haemorrhage. Neuroscience Letters, 1994, 170, 67-70.	2.1	65
395	Human in vivo evidence for trigeminovascular activation in cluster headache Neuropeptide changes and effects of acute attacks therapies. Brain, 1994, 117, 427-434.	7.6	621
396	Neuropeptide Y inhibits adenylyl cyclase activity in rabbit retina. Acta Ophthalmologica, 1994, 72, 326-331.	1,1	9

#	Article	IF	Citations
397	Perivascular neuropeptides (NPY, VIP, CGRP and SP) in human brain vessels after subarachnoid haemorrhage. Acta Neurologica Scandinavica, 1994, 90, 324-330.	2.1	42
398	The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology, 1993, 33, 48-56.	5.3	1,021
399	Cortical Spreading Depression Does Not Result in the Release of Calcitonin Gene-Related Peptide into the External Jugular Vein of the Cat: Relevance to Human Migraine. Cephalalgia, 1993, 13, 180-183.	3.9	40
400	PACAP, a VIP-like Peptide: Immunohistochemical Localization and Effect upon Cat Pial Arteries and Cerebral Blood Flow. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 291-297.	4.3	115
401	5â€Hydroxytryptamine receptor characterizations of human cerebral, middle meningeal and temporal arteries: regional differences. Acta Physiologica Scandinavica, 1993, 147, 141-150.	2.2	46
402	Interactions Between Cultured Bovine Arterial Endothelial and Smooth Muscle Cells: Studies on Uptake and Degradation of Low Density Lipoproteins by Smooth Muscle Cells. Basic and Clinical Pharmacology and Toxicology, 1993, 73, 269-273.	0.0	0
403	Examination of the involvement of neuropeptide Y (NPY) in cerebral autoregulation using the novel NPY antagonist PP56. Neuropeptides, 1993, 24, 27-33.	2.2	17
404	Cortical blood flow during head-up postural change in subjects with orthostatic hypotension. Clinical Autonomic Research, 1993, 3, 311-318.	2.5	31
405	A novel ETAâ€receptor antagonist, FR 139317, inhibits endothelinâ€induced contractions of guineaâ€pig pulmonary arteries, but not trachea. British Journal of Pharmacology, 1993, 108, 448-452.	5.4	58
406	Peptidergic innervation of human epicardial coronary arteries Circulation Research, 1993, 73, 579-588.	4.5	101
407	Neuropeptides in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Dementia with Frontotemporal Lobe Degeneration. Dementia and Geriatric Cognitive Disorders, 1993, 4, 167-171.	1.5	22
408	NOS neurones lie near branchings of cortical arteriolae. NeuroReport, 1993, 4, 112.	1.2	53
409	Characterization of endothelin-A receptors in the cerebral circulation. NeuroReport, 1993, 4, 441-443.	1.2	38
410	Inhibition of Endothelin (ET-1) Induced Pressor Responses by the Endothelin (ETA) Receptor Antagonist FR139317 in the Pithed Rat. Blood Pressure, 1992, 1, 108-112.	1.5	14
411	Sensory Nerve Terminal Activity in Severe Hypertension as Reflected by Circulating Calcitonin Gene-Related Peptide (CGRP) and Substance P. Blood Pressure, 1992, 1, 223-229.	1.5	14
412	Evidence for multiple endothelin receptors in the guineaâ€pig pulmonary artery and trachea. British Journal of Pharmacology, 1992, 105, 376-380.	5.4	33
413	Characterization of Calcitonin Gene?Related Peptide Receptors in Human Cerebral Vessels Annals of the New York Academy of Sciences, 1992, 657, 435-440.	3.8	32
414	Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: Comparison with cerebral and temporal arteries. Peptides, 1992, 13, 527-536.	2.4	101

#	Article	IF	Citations
415	Cutaneous Sensory Stimulation Leading to Facial Flushing and Release of Calcitonin Gene-Related Peptide. Cephalalgia, 1992, 12, 53-56.	3.9	28
416	Sumatriptan is a Potent Vasoconstrictor of Human Dural Arteries Via a 5-HT1-Like Receptor. Cephalalgia, 1992, 12, 202-205.	3.9	65
417	Reduced levels of calcitonin gene-related peptide-like immunoreactivity in human brain vessels after subarachnoid haemorrhage. Neuroscience Letters, 1991, 121, 151-154.	2.1	58
418	Sumatriptan Reverses the Changes in Calcitonin Gene-Related Peptide Seen in the Headache Phase of Migraine. Cephalalgia, 1991, 11, 3-4.	3.9	78
419	Analysis of the Vasoconstrictor Effects of Sumatriptan on Human Cranial Arteries Cephalalgia, 1991, 11, 210-211.	3.9	7
420	Tachykinins (Substance P, Neurokinin A, Neuropeptide K, and Neurokinin B) in the Cerebral Circulation: Vasomotor Responses in vitro and in situ. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, 567-575.	4.3	76
421	Neuropeptide Y and vasoactive intestinal peptide in experimental subarachnoid hemorrhage: immunocytochemistry, radioimmunoassay and pharmacology. Acta Neurologica Scandinavica, 1991, 83, 103-109.	2.1	20
422	Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders. European Journal of Clinical Pharmacology, 1991, 40, 7-15.	1.9	27
423	Neuropeptide Y and the Cerebral Circulation. Journal of Cerebral Blood Flow and Metabolism, 1990, 10, 591-601.	4.3	46
424	Involvement of Perivascular Sensory Fibers in the Pathophysiology of Cerebral Vasospasm following Subarachnoid Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 1990, 10, 602-607.	4.3	70
425	γ ₂ â€MSH in congestive heart failure: relation to atrial natriuretic peptide, arginine vasopressin and catecholamines. Journal of Internal Medicine, 1990, 227, 183-187.	6.0	11
426	Extracerebral manifestations in migraine. A peptidergic involvement?. Journal of Internal Medicine, 1990, 228, 299-304.	6.0	25
427	Changes in the levels of neuropeptide Y-LI in the external jugular vein in connection with vasoconstriction following subarachnoid haemorrhage in man. Acta Neurochirurgica, 1990, 107, 75-81.	1.7	27
428	Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology, 1990, 28, 183-187.	5.3	1,386
429	Calcitonin gene-related peptide-LI in subarachnoid haemorrhage in man. Signs of activation of the trigemino-cerebrovascular system?. British Journal of Neurosurgery, 1990, 4, 171-179.	0.8	7 5
430	Neuropeptide Y in cerebrovascular function: comparison of membrane potential changes and vasomotor responses evoked by NPY and other vasoconstrictors in the guinea pig basilar artery. Neuroscience Letters, 1990, 114, 117-122.	2.1	22
431	Neuropeptide Y antagonistic properties of D-myo-inositol-1.2.6-trisphosphate in guinea pig basilar arteries. Neuropeptides, 1990, 17, 99-105.	2.2	79
432	Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides, 1990, 16, 69-75.	2.2	213

#	Article	IF	CITATIONS
433	Cerebrovascular responses to capsaicin <i>in vitro</i> and <i>in situ</i> . British Journal of Pharmacology, 1990, 100, 312-318.	5.4	69
434	Evidence that calcitonin gene-related peptide contributes to the capsaicin-induced relaxation of guinea pig cerebral arteries. Regulatory Peptides, 1990, 31, 167-178.	1.9	44
435	Congestive heart failure: involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibres. European Journal of Clinical Investigation, 1990, 20, 85-89.	3.4	38
436	Cerebral autoregulation. Cerebrovascular and Brain Metabolism Reviews, 1990, 2, 161-92.	2.0	1,007
437	Perivascular Peptide Transmitters: Innervation and Release in Migraine. Cephalalgia, 1989, 9, 19-20.	3.9	1
438	Peptide-Containing Nerves in the Rat Femoral Artery and Vein. Journal of Vascular Research, 1989, 26, 254-271.	1.4	18
439	Neurokinin A and Temporal Muscle Blood Flow. Cephalalgia, 1989, 9, 74-75.	3.9	0
440	The Role of Calcitonin Gene-Related Peptide in Neurally Mediated Facial Flushing. Cephalalgia, 1989, 9, 290-291.	3.9	0
441	Sensory Neuropeptides in Human Cranial Arteries. Mode of Action. Cephalalgia, 1989, 9, 25-26.	3.9	0
442	Characterization of 5-HT Receptors Mediating Contraction of Human Cerebral, Meningeal and Temporal Arteries: Target for GR 43175 in Acute Treatment of Migraine?. Cephalalgia, 1989, 9, 39-40.	3.9	14
443	Effects of Calcium Entry Blockers on Human Platelet Metabolism Measured by Microcalorimetry. Human Toxicology, 1989, 8, 131-133.	0.9	2
444	Axonal tracing of autonomic nerve fibers to the superficial temporal artery in the rat. Cell and Tissue Research, 1989, 256, 559-65.	2.9	33
445	Mechanisms of Action of Endothelin on Isolated Feline Cerebral Arteries: In vitro Pharmacology and Electrophysiology. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 743-747.	4.3	59
446	Acetylcholine and Vasoactive Intestinal Peptide in Cerebral Blood Vessels: Effect of Extirpation of the Sphenopalatine Ganglion. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 204-211.	4.3	67
447	Retrograde Tracing of Nerve Fibers to the Rat Middle Cerebral Artery with True Blue: Colocalization with Different Peptides. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 212-218.	4.3	166
448	Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistry. Journal of the Autonomic Nervous System, 1989, 26, 69-75.	1.9	101
449	Extracerebral Levels of Circulating Vasoactive Peptides during Migraine Headache. Cephalalgia, 1989, 9, 292-293.	3.9	9
450	Endothelin, An Endothelium Derived Contractile Peptide, is a Potent Vasoconstrictor of Cerebral Blood Vessels: Mode of Action in Isolated Arteries. Cephalalgia, 1989, 9, 45-46.	3.9	0

#	Article	IF	CITATIONS
451	The Effects of Capsaicin on NKA and NKB in the Trige-Mino-Cerebrovascular System. Cephalalgia, 1989, 9, 47-48.	3.9	19
452	Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man. Journal of Human Hypertension, 1989, 3, 267-70.	2.2	16
453	Neuropeptides in the cerebral circulation. Cerebrovascular and Brain Metabolism Reviews, 1989, 1, 230-52.	2.0	76
454	Effect of Pregnancy and Sex Steroids on α ₁ â€Adrenoceptor Mechanisms in the Guineaâ€Pig Uterine Vascular Bed. Basic and Clinical Pharmacology and Toxicology, 1988, 63, 375-381.	0.0	18
455	Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Annals of Neurology, 1988, 23, 193-196.	5.3	814
456	Effect of Stimulation of the Sphenopalatine Ganglion on Cortical Blood Flow in the Rat. Journal of Cerebral Blood Flow and Metabolism, 1988, 8, 875-878.	4.3	132
457	Neurokinin A in cerebral vessels: characterization, localization and effects in vitro. Regulatory Peptides, 1988, 20, 181-197.	1.9	90
458	Heterogeneous vasomotor responses of anatomically distinct feline cerebral arteries. British Journal of Pharmacology, 1988, 94, 423-436.	5.4	69
459	Characterization of histamine receptors in isolated human cerebral arteries. British Journal of Pharmacology, 1988, 94, 901-907.	5.4	36
460	Neuronal versus endothelial origin of vasoactive acetylcholine in pial vessels. Brain Research, 1987, 420, 391-396.	2.2	50
461	Characterization of tachykinin receptors in isolated basilar arteries of guineaâ€pig. British Journal of Pharmacology, 1987, 90, 553-559.	5.4	28
462	Variability Of The Human Vascular Alpha-Adrenoceptor. Cephalalgia, 1987, 7, 112-114.	3.9	1
463	Peptide-containing nerve fibers in human cerebral arteries: Immunocytochemistry, radioimmunoassay and in vitro pharmacology. Annals of Neurology, 1987, 21, 431-437.	5.3	169
464	The concept of coupling blood flow to brain function: Revision required?. Annals of Neurology, 1987, 22, 289-297.	5.3	295
465	Calcitonin Gene-Related Peptide and Cerebral Blood Vessels: Distribution and Vasomotor Effects. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 720-728.	4.3	282
466	Nerve Fibers Containing Neuropeptide Y in the Cerebrovascular Bed: Immunocytochemistry, Radioimmunoassay, and Vasomotor Effects. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 45-57.	4.3	135
467	Concentrations of Putative Neurovascular Transmitters in Major Cerebral Arteries and Small Pial Vessels of Various Species. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 497-501.	4.3	40
468	Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regulatory Peptides, 1986, 15, 1-23.	1.9	306

#	Article	IF	Citations
469	Peptide-containing nerve fibres in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranial pain?. Pain, 1986, 27, 391-399.	4.2	47
470	Demonstration of Perivascular Peptides and Changes in Concentration with Age in Man. Gerontology, 1986, 32, 50-52.	2.8	10
471	Calcitonin gene-related peptide: functional role in cerebrovascular regulation Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 5731-5735.	7.1	453
472	Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Annals of Neurology, 1986, 20, 496-501.	5.3	89
473	On the Pathogenesis of Regional Cerebral Ischemia in Intracranial Hemorrhage. A Causal Influence of Potassium?. Pediatric Research, 1986, 20, 478-480.	2.3	24
474	Methylxanthines Reduce in vitro Human Overall Platelet Metabolism as Measured by Microcalorimetry. Acta Medica Scandinavica, 1986, 220, 185-188.	0.0	9
475	Functional Bases for a Central Serotonergic Involvement in Classic Migraine: A Speculative View. Cephalalgia, 1985, 5, 69-78.	3.9	26
476	Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels. Acta Physiologica Scandinavica, 1985, 124, 467-469.	2.2	125
477	Characterization of the contractile effect of neuropeptide Y in feline cerebral arteries. Acta Physiologica Scandinavica, 1985, 125, 33-41.	2.2	107
478	NEUROPEPTIDE Y AND CEREBRAL BLOOD FLOW. Lancet, The, 1985, 325, 1271.	13.7	15
479	Vasomotor responses of cerebral arterioles <i>in situ</i> to putative dopamine receptor agonists. British Journal of Pharmacology, 1985, 85, 403-410.	5.4	44
480	Functional role of perivascular peptides in the control of cerebral circulation. Trends in Neurosciences, 1985, 8, 126-131.	8.6	215
481	Distribution and vasomotor effects of peptide HI (PHI) in feline cerebral blood vessels in vitro and in situ. Regulatory Peptides, 1985, 10, 345-356.	1.9	43
482	Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P. Neuroscience Letters, 1985, 62, 131-136.	2.1	386
483	Neuropeptide Y-like immunoreactivity in perivascular nerve fibres of the guinea-pig. Regulatory Peptides, 1985, 10, 243-257.	1.9	133
484	Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neuroscience Letters, 1985, 58, 213-217.	2.1	360
485	Cerebrovascular Smooth Muscle Reactivity: A Critical Appraisal of in vitro and in situ Techniques. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 129-139.	4.3	53
486	Neuropeptide Y: Immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta Physiologica Scandinavica, 1984, 122, 155-163.	2.2	157

#	Article	IF	CITATIONS
487	Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. British Journal of Pharmacology, 1984, 83, 519-525.	5.4	377
488	Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regulatory Peptides, 1984, 8, 225-235.	1.9	702
489	Effects of Bradykinin on Pial Arteries and Arterioles <i>in vitro</i> and <i>in situ</i> . Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 231-237.	4.3	79
490	Responses of Isolated Feline and Human Cerebral Arteries to Prostacyclin and Some of its Metabolites. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 238-245.	4.3	44
491	Effects of Kininase II Inhibitors on the Vasomotor Response to Bradykinin of Feline Intracranial and Extracranial Arteries in vitro and in situ. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 339-345.	4.3	20
492	Effects of Topical Application of a Calcium Antagonist (Nifedipine) on Feline Cortical Pial Microvasculature under Normal Conditions and in Focal Ischemia. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 44-50.	4.3	96
493	Nerve Fibres Containing Gastrin-Releasing Peptide around Pial Vessels. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 386-390.	4.3	39
494	Central serotonergic nerves project to the pial vessels of the brain. Nature, 1983, 306, 55-57.	27.8	199
495	Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels*. Acta Physiologica Scandinavica, 1983, 117, 49-61.	2.2	404
496	Pharmacological characterization of postjunctional αâ€adrenoceptors in isolated feline cerebral and peripheral arteries. Acta Physiologica Scandinavica, 1983, 117, 63-73.	2.2	67
497	Substance P: Localization, concentration and release in cerebral arteries, choroid plexus and dura mater. Cell and Tissue Research, 1983, 234, 1-7.	2.9	101
498	Neuropeptide Y: Cerebrovascular innervation an vasomotor effects in the cat. Neuroscience Letters, 1983, 43, 79-84.	2.1	323
499	Characterization of adenosine receptors in isolated cerebral arteries of cat. British Journal of Pharmacology, 1983, 80, 631-637.	5.4	125
500	Functional role for vasoactive intestinal polypeptide in the caudate nucleus: a 2-deoxy[14C]glucose investigation Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 1472-1476.	7.1	44
501	Feline cerebral veins and arteries: comparison of autonomic innervation and vasomotor responses. Journal of Physiology, 1982, 325, 161-173.	2.9	97
502	Antagonism by (Dâ€Pro ² , Dâ€Trp ^{7,9})â€substance P of the cerebrovascular dilatation induced by substance P. Acta Physiologica Scandinavica, 1982, 116, 411-416.	2.2	31
503	Characterization of 5-hydroxytryptamine receptors in human temporal arteries: Comparison between migraine sufferers and nonsufferers. Annals of Neurology, 1982, 12, 272-277.	5.3	20
504	Comparison of the effects of potassium and pH on the calibre of cerebral veins and arteries. Pflugers Archiv European Journal of Physiology, 1982, 393, 95-98.	2.8	40

#	Article	IF	Citations
505	Substance P: immunohistochemical localization and effect upon cat pial arteries in vitro and in situ Journal of Physiology, 1981, 318, 251-258.	2.9	197
506	Effects of prostaglandin E ₁ , E ₂ , and F _{2$\hat{1}\pm <$/sub> on isolated pial arteries of cat. Acta Physiologica Scandinavica, 1981, 111, 487-490.}	2.2	6
507	VIP nerve fibres around peripheral blood vessels. Acta Physiologica Scandinavica, 1981, 112, 65-70.	2.2	101
508	Characterization of the postsynaptic aâ€adrenoceptor in isolated feline cerebral arteries. Acta Physiologica Scandinavica, 1981, 112, 105-107.	2.2	40
509	Adrenergic, Cholinergic and Peptidergic Nerve Fibres in Dura Mater Involvement in Headache?. Cephalalgia, 1981, 1, 175-179.	3.9	80
510	Direct Vascular Effects of Agents Used in the Pharmacotherapy of Cerebrovascular Disease on Isolated Cerebral Vessels. Journal of Cerebral Blood Flow and Metabolism, 1981, 1, 117-128.	4.3	24
511	Action of 4-aminopyridine on the cerebral circulation. Acta Neurologica Scandinavica, 1981, 63, 122-130.	2.1	3
512	Cerebral microembolization in the rat: Changes in blood-brain barrier permeability and cerebral blood flow as related to the degree of ischemia. Acta Neurologica Scandinavica, 1981, 64, 88-100.	2.1	18
513	VIP (vasoactive intestinal polypeptide)-containing nerves of intracranial arteries in mammals. Cell and Tissue Research, 1980, 208, 135-42.	2.9	142
514	Histofluorescence study on monoamine entry into the brain before and after opening of the blood-brain barrier by various mechanisms. Acta Neuropathologica, 1979, 47, 145-150.	7.7	22
515	Pharmacological analysis of 5-hydroxytryptamine receptors in isolated intracranial and extracranial vessels of cat and man Circulation Research, 1978, 42, 143-151.	4.5	156
516	Influence of the Cerebrovascular Sympathetic Innervation on Regional Flow, Autoregulation, and Bloodâ€Brain Barrier Function. Novartis Foundation Symposium, 1978, , 69-95.	1.1	10
517	Effects of Intraventricular 6â€Hydroxydopamine on Cerebrovascular CO ₂ Reactivity in Anesthetized Rats. Acta Physiologica Scandinavica, 1977, 101, 122-125.	2.2	21
518	Regional distribution of mast cells containing histamine, dopamine, or 5â€hydroxytryptamine in the mammalian brain. Neurology, 1977, 27, 878-878.	1.1	182
519	Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Research, 1976, 115, 377-393.	2.2	438
520	Immunohistochemical localization of a vasodilatory polypeptide (VIP) in cerebrovascular nerves. Brain Research, 1976, 113, 400-404.	2.2	365
521	Characterization of Serotoninâ€Receptors in Intracranial and Extracranial Vessels. Acta Physiologica Scandinavica, 1976, 97, 523-525.	2.2	37
522	Amine mechanisms in the cerebral circulation. Pharmacological Reviews, 1976, 28, 275-348.	16.0	108

#	Article	IF	CITATIONS
523	Adrenergic innervation of the mammalian choroid plexus. American Journal of Anatomy, 1974, 139, 299-307.	1.0	63
524	Influence of initial tension and changes in sensitivity during amine-induced contractions of pial arteries in vitro. Archives Internationales De Pharmacodynamie Et De ThÃ@rapie, 1974, 208, 235-42.	0.2	16
525	Are brain vessels innervated also by central (non-sympathetic) adrenergic neurones?. Brain Research, 1973, 63, 496-499.	2.2	155
526	Concentration of Noradrenaline in Pial Vessels, Choroid Plexus, and Iris during Two Weeks after Sympathetic Ganglionectomy or Decentralization. Acta Physiologica Scandinavica, 1972, 85, 201-206.	2.2	76
527	Cholinergic mechanisms in pial vessels. Cell and Tissue Research, 1972, 134, 311-325.	2.9	177